A Phase 1 interventional study of PG4 vaccine in Buffer 1 with low dose PA-001 and PG4 in Buffer 1 with low dose PA-002 in Streptococcus Pneumoniae, sponsored by Pfizer. Active, not recruiting at 20 sites in United States. Open to participants aged 65 Years to 84 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-22.
Sponsored by Pfizer · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to learn about the safety and tolerability of a pneumococcal vaccine in adults.
Participants will receive either:
Participants will take part in this study for up to 18 months depending on which group they are assigned to. During this time, the participants will receive up to two doses of study vaccine or comparator and take part in follow-up visits.
At these clinic visits, participants will be asked if any side effects were experienced. The participants will also have to give blood samples during clinic visits.
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Biological: PG4 vaccine in Buffer 1 with low dose PA-001
Biological: PG4 vaccine in Buffer 1 with low dose PA-001
Biological: PG4 in Buffer 1 with low dose PA-002
Biological: PG4 in Buffer 1 with low dose PA-002
Biological: PG4 in Buffer 1 with high dose PA-001
Biological: PG4 in Buffer 1 with high dose PA-001
Biological: PG4 vaccine in Buffer 1 with high dose PA-002
Biological: PG4 vaccine in Buffer 1 with high dose PA-002
Biological: PG4 vaccine in Buffer 2 · Biological: Saline injection
Biological: PG4 vaccine in Buffer 2 · Biological: Saline injection
Biological: 20-valent pneumococcal conjugate vaccine · Biological: Saline injection
Biological: 20-valent pneumococcal conjugate vaccine · Biological: Saline injection
Multivalent pneumococcal conjugate vaccine
Multivalent pneumococcal conjugate vaccine
Multivalent pneumococcal conjugate vaccine
Multivalent pneumococcal conjugate vaccine
Multivalent pneumococcal conjugate vaccine
(20vPnC)
Placebo
Percentage of participants reporting prespecified local reactions after each dose.
Prespecified local reactions (redness, swelling, and pain at the injection site) occurring within 7 days of each dose administered in the study.
Time frame: Within 7 days after each study intervention.
Percentage of participants reporting prespecified systemic reactions after each dose.
Prespecified systemic reactions (fever, vomiting, diarrhea, headache, fatigue, muscle pain, and joint pain) occurring within 7 days of each dose administered in the study.
Time frame: Within 7 days after each study intervention.
Percentage of participants reporting adverse events.
Adverse Events (AEs) occurring from Dose 1 through 1 month after the last vaccination
Time frame: From signing of the ICD to 1 month after last study intervention.
Percentage of participants reporting serious adverse events.
Serious Adverse Events (SAEs) occurring from Dose 1 through 6 months after the last vaccination.
Time frame: From signing of the ICD to 6 months after the last study intervention.
Percentage of participants reporting serious adverse events.
Serious Adverse Events (SAEs) occurring from Dose 1 through 12 months after the last vaccination.
Time frame: From signing of the ICD to 12 months after the last study intervention.
Percentage of participants with abnormal hematology and chemistry laboratory values.
Any abnormal hematology or chemistry laboratory values as compared to baseline within 2 weeks after each study intervention.
Time frame: Within 2 weeks after each study intervention.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Started Jul 2025 (actual). Primary completion is estimated for Oct 2027, 26 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.